J&J extends R&D collaboration with Midatech Pharma on second molecule

Mar. 10, 2022 12:10 PM ETJohnson & Johnson (JNJ)By: Jonathan Block, SA News Editor1 Comment

Janssen headquarters in Silicon Valley

Sundry Photography/iStock Editorial via Getty Images

  • Johnson & Johnson's (JNJ -0.6%) Janssen unit and U.K.-based Midatech Pharma are extending an R&D collaboration to include a second molecule.
  • The two companies have previously collaborated on MTX213 utilizing Midatech's Q-Sphera platform, which the company says focuses on long-acting injectables that use proprietary 3D printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics.
  • According to a Midatech news release, work on the second molecule "will concentrate on maximizing drug loading and optimizing in vitro duration of release."
  • Read why Seeking Alpha contributor Daniel Schonberger says J&J (JNJ -0.6%) is a hold.

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.